Rational for Targeting APRIL in IgA Nephropathy
Time: 1:45 pm
day: Pre-Conference Seminar Day
Details:
- Providing an overview of the Sibeprenlimab development program
- Reviewing the latest data from the phase 2 trial
- Optimizing trial design for the phase 3 program: The Visionary Trial Design
